Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Core Insights - Organovo Holdings, Inc. has announced the acquisition of its FXR program by Eli Lilly and Company, which includes the lead asset FXR314 [1][2] - This acquisition is seen as a significant milestone for Organovo in advancing treatments for inflammatory bowel disease (IBD) using proprietary 3D human tissue models [2] Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues, utilizing proprietary technology to mimic native human tissue characteristics [3]